Georgia Mesothelioma Fact Sheet
While mesothelioma is a problem in all states, the specific incident rate for Georgia is 0.7 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in GA, recent GA mesothelioma-related court cases, mesothelioma specialists in GA and potential asbestos hotspots in Georgia.
Georgia Mesothelioma Info
By clicking on the above tabs, you will find information on mesothelioma specific to the state of Georgia
Georgia Research and Clinical Trials
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Georgia Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Georgia Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.
Georgia Doctors and Hospitals
This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.
Georgia Cases
This is a partial list of relevant court cases on mesothelioma in your state.
Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.
John Crane, Inc. v. Jones
S03G1791. , SUPREME COURT OF GEORGIA, November 8, 2004, Decided.
S03G1791. , SUPREME COURT OF GEORGIA, November 8, 2004, Decided.
Putzel Elec. Contrs. v. Jones
A06A1039 , COURT OF APPEALS OF GEORGIA, November 22, 2006, Decided
A06A1039 , COURT OF APPEALS OF GEORGIA, November 22, 2006, Decided
Flowers v. Union Carbide Corp.
A04A1854. , COURT OF APPEALS OF GEORGIA, January 27, 2005, Decided
A04A1854. , COURT OF APPEALS OF GEORGIA, January 27, 2005, Decided
John Crane, Inc. v. Highsmith
A04A1507. , COURT OF APPEALS OF GEORGIA, November 24, 2004, Decided
A04A1507. , COURT OF APPEALS OF GEORGIA, November 24, 2004, Decided
John Crane, Inc. v. Jones
A03A0301 , COURT OF APPEALS OF GEORGIA, SECOND DIVISION, July 2, 2003, Decided
A03A0301 , COURT OF APPEALS OF GEORGIA, SECOND DIVISION, July 2, 2003, Decided
Williams v. Flintkote Co.
A02A0782. , COURT OF APPEALS OF GEORGIA, FIRST DIVISION, June 27, 2002, Decided
A02A0782. , COURT OF APPEALS OF GEORGIA, FIRST DIVISION, June 27, 2002, Decided
Kellogg Co. v. Pinkston
A01A1789. , COURT OF APPEALS OF GEORGIA, SECOND DIVISION, December 11, 2001, Decided
A01A1789. , COURT OF APPEALS OF GEORGIA, SECOND DIVISION, December 11, 2001, Decided
Hoffman v. Ac&S, Inc.
A00A2409. , COURT OF APPEALS OF GEORGIA, March 14, 2001, Decided
A00A2409. , COURT OF APPEALS OF GEORGIA, March 14, 2001, Decided
Hospitals and Cancer Centers
Dong M. Shin, MD, FACP
Director Clinical and Translational Cancer Prevention Program
Department: Hematology and Medical Oncology
Appointments: 404-778-1900
wci.referrals@emoryhealthcare.org
1365 Clifton Road, Bldg. C Atlanta, GA 30322
Dong M. Shin, MD, FACP
Director Clinical and Translational Cancer Prevention Program
Department: Hematology and Medical Oncology
Appointments: 404-778-1900
wci.referrals@emoryhealthcare.org
1365 Clifton Road, Bldg. C Atlanta, GA 30322
| City | Site |
|
Stephens Firebrick Plant | |
| Athens |
Athens College Curtis Mathis |
| Atlanta |
Baptist Home Mission Chevron Bulk Storage Chevron Plant FBI Bldg International Paper Company Mead Paper Mill Mobil Bulk Storage Plant Shell Plant Southern Heat Treat Texaco Bulk Storage Plant Tri City Bulk Storage VA Hospital |
| Augusta |
Columbia Nitrogen Continental Can Co Cox Newprint Danield Fields Air Force Base Nitrogen liquid fertilizer plant Proctor & Gamble |
| Brunswick |
American Sianemy Babcock & Wilcox Plant Bemis Bag Building Georgia Power Georgia Pacific Paper Mill |
| Carrollton |
Crusable Steel Mill |
| Carterville |
Carterville Power Plant Georgia Power Plant |
| Crossett |
Georgia Pacific Paper Mill |
| Fort Benning |
Fort Benning |
| Juliette |
Scherer Power Plant |
| Macon |
Armstrong Cork Corporation Burns Brick Company Carlin Tile Georgia Kaolin Post Office Warner Robbins AFB |
| Marietta |
Lockheed Aircraft Plant |
| Mellewam |
Georgia Pacific Paper Mill |
| Millville |
Georgia Power & Light] |
| New Brunswick |
New Brunswick Powder Plant |
| Newman |
Plant Yates Power Plant |
| Oglethorpe |
Buckeye Paper Mill |
| Oxford |
Hercules Refinery |
| Perry |
Pabst Brewery |
| Rome |
Rome Craft Paper Mill |
| Savannah |
Civilian Shipyard Dupont |
Research
Bockman, Dale E. Experimentally-induced Pancreatic Adenocarcinoma
Grant: 1R26CA022063-01
Grant: 1R26CA022063-01
Abstract: The goals of this study are twofold: 1) verify and extend an experimental
animal model for the study of pancreatic adenocarcinoma in which tumors are
induced by the direct implantation of 7, 12-dimethylbenz(a)anthracene; 2) to
test other chemicals for their carcinogenic potential when implanted into the
pancreas. The morphology and behavior of the tumors will be characterized by
correlated light and electron microscopy. Evidence of invasiveness and
metastatic capabilities of the tumors will be examined. The cell(s) of origin
of the tumors will be sought by studying early stages of tumor induction. The
implantation model is well suited for such studies because the focus of
carcinogenesis is in the area immediately adjacent to the implant. The
implantation model has distinct advantages over those models employing systemic
administration of large quantities of carcinogen. These advantages are: 1) the
high incidence of tumors (80%); 2) the relatively short induction time (119
days); 3) the absence of primary tumors in other organs; for example, liver,
stomach, or lungs; 4) there is no administration of large amounts of carcinogen
with its attendant systemic toxicity; and 5) there is no impairment of immune
and host defenses by systemic toxicity; and 5) there is no impairment of immune
and host defenses by systemic poisoning of the host animal. Tumors developed in
this model will be compared with the hamster model and with human pancreatic
adenocarcinoma. Several parameters of tumor induction will be investigated,
including dosage level, method of implantation, alterations with increasing
time, age of animals at the time of implantation, species differences, and the
effects of different carcinogens. Validation of the implantation model will
make possible further studies directed toward understanding the development of
human pancreatic adenocarcinoma. It is anticipated that this model can be
studied by methods employing cell culture, transplantation, and chemotherapy.
The findings derived from this model should contribute to the general
understanding of chemical carcinogenesis.
Tags: Models, Biological, Neoplasms Of Pancreas, Neoplastic Transformation, Carcinogens, Chemical Cyclics, Carbopolycyclics, Benzanthracenes, Dosage And Route, Route Of Administration, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms, Adenocarcinoma, Neoplastic Growth, Neoplasms Invasiveness, Neoplastic Growth, Neoplasms Metastasis, Neoplastic Transformation, Carcinogens, Screening, Tissue Compatibility-transplant, Implant Age (animal), Mammals, Rodents, Myomorpha, Hamsters*, Mammals, Rodents, Myomorpha, Rats (laboratory)*, Optics, Microscopy, Electron Scanning*, Optics, Microscopy, Electron*
Tags: Models, Biological, Neoplasms Of Pancreas, Neoplastic Transformation, Carcinogens, Chemical Cyclics, Carbopolycyclics, Benzanthracenes, Dosage And Route, Route Of Administration, Neoplasms Of Body Cavities, Mesothelioma, Neoplasms, Adenocarcinoma, Neoplastic Growth, Neoplasms Invasiveness, Neoplastic Growth, Neoplasms Metastasis, Neoplastic Transformation, Carcinogens, Screening, Tissue Compatibility-transplant, Implant Age (animal), Mammals, Rodents, Myomorpha, Hamsters*, Mammals, Rodents, Myomorpha, Rats (laboratory)*, Optics, Microscopy, Electron Scanning*, Optics, Microscopy, Electron*
- Followup Grant: 2R26CA022063-03
Vogler, William R. Eastern Cooperative Oncology Group
Grant: 1U10CA049762-01A2
Grant: 1U10CA049762-01A2
Abstract: This application requests support to permit Emory University to participate
in clinical trials conducted under the auspices of the Eastern Cooperative
Oncology Group. This is a multiple disciplined approach involving
collaboration between medical and surgical oncologists, radiation
therapists, and pathologists. Emory serves as a regional referral center
for cancer and over 2500 newly diagnosed patients are seen annually.
The objectives of this proposal are to improve therapy of cancer through
research and provide a database for scientific questions regarding cancer
biology, epidemiology and clinical trials methodology.
The specific aims are to increase case accruals to cooperative group
protocols and to expand Emory's participation in the science involved in
development of group protocols. Faculty members participate in Group
scientific committees. Investigations ongoing at Emory with potential for
expansion into group studies are the use of ether phospholipids as purging
agents for autologous bone marrow transplantation, the use of calcitonin
gene rearrangements for detection of minimal residual disease, combination
chemotherapy programs for autologous and allogeneic bone marrow
transplantation for lymphomas, hematopoietic growth factors on
thrombocytopoiesis, the use of viral oncolysates in melanoma, and the use
of cytokine therapy in human colorectal cancer.
Tags: Cancer Prevention, Human Therapy Evaluation, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Genetics, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Therapy Bacillus Calmette Guerin Vaccine, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Androgen Inhibitor, Anthracycline, Antineoplastic, Autologous Transplantation, Biological Response Modifier, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Brain Neoplasm, Breast Neoplasm, Bronchogenic Carcinoma, Calcitonin, Cancer Information System, Cancer Risk, Castration, Cis Platinum Compound, Clinical Study /trial, Colony Stimulating Factor, Colorectal Neoplasm, Combination Chemotherapy, Community Health Service, Cooperative Study, Cyclophosphamide, Cystectomy, Cytosine Arabinoside, Deoxycoformycin, Dyserythropoietic Anemia, Ether, Etoposide, Fluorouracil, Formamide, Gene Rearrangement, Germ Cell Neoplasm, Hairy T Cell Leukemia, Head /neck Neoplasm, Homologous Transplantation, Ifosfamide, Interferon, Interleukin 3, Interleukin 6, Kidney Neoplasm, Leucovorin, Levamisole, Lymphocytic Leukemia, Lymphoma, Melanoma, Melphalan, Mesothelioma, Metastasis, Methotrexate, Mitomycin C, Mitoxantrone, Multiple Myeloma, Nasopharyngeal Neoplasm, Neoplasm /cancer Diagnosis, Neoplasm /cancer Hormone Therapy, Neoplasm /cancer Immunology, Neoplasm /cancer Surgery, Neoplastic Cell, Oat Cell Carcinoma, Osteogenic Sarcoma, Ovary Neoplasm, Phospholipid, Prednisone, Prostate Neoplasm, Rectum Neoplasm, Sarcoma, Tamoxifen, Therapy Compliance, Thrombopoiesis, Thyroid Neoplasm, Tumor Antigen, Urinary Bladder Epithelium, Vincristine Human Clinical Subject, Polymerase Chain Reaction, Tissue /cell Culture
Tags: Cancer Prevention, Human Therapy Evaluation, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Genetics, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Therapy Bacillus Calmette Guerin Vaccine, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Androgen Inhibitor, Anthracycline, Antineoplastic, Autologous Transplantation, Biological Response Modifier, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Brain Neoplasm, Breast Neoplasm, Bronchogenic Carcinoma, Calcitonin, Cancer Information System, Cancer Risk, Castration, Cis Platinum Compound, Clinical Study /trial, Colony Stimulating Factor, Colorectal Neoplasm, Combination Chemotherapy, Community Health Service, Cooperative Study, Cyclophosphamide, Cystectomy, Cytosine Arabinoside, Deoxycoformycin, Dyserythropoietic Anemia, Ether, Etoposide, Fluorouracil, Formamide, Gene Rearrangement, Germ Cell Neoplasm, Hairy T Cell Leukemia, Head /neck Neoplasm, Homologous Transplantation, Ifosfamide, Interferon, Interleukin 3, Interleukin 6, Kidney Neoplasm, Leucovorin, Levamisole, Lymphocytic Leukemia, Lymphoma, Melanoma, Melphalan, Mesothelioma, Metastasis, Methotrexate, Mitomycin C, Mitoxantrone, Multiple Myeloma, Nasopharyngeal Neoplasm, Neoplasm /cancer Diagnosis, Neoplasm /cancer Hormone Therapy, Neoplasm /cancer Immunology, Neoplasm /cancer Surgery, Neoplastic Cell, Oat Cell Carcinoma, Osteogenic Sarcoma, Ovary Neoplasm, Phospholipid, Prednisone, Prostate Neoplasm, Rectum Neoplasm, Sarcoma, Tamoxifen, Therapy Compliance, Thrombopoiesis, Thyroid Neoplasm, Tumor Antigen, Urinary Bladder Epithelium, Vincristine Human Clinical Subject, Polymerase Chain Reaction, Tissue /cell Culture
- Followup Grant: 5U10CA049762-02
- Followup Grant: 5U10CA049762-03
Vogler, William R. Cooperative Oncology Group
Grant: 3U10CA049762-03S1
Grant: 3U10CA049762-03S1
Abstract: This application requests support to permit Emory University to participate
in clinical trials conducted under the auspices of the Eastern Cooperative
Oncology Group. This is a multiple disciplined approach involving
collaboration between medical and surgical oncologists, radiation
therapists, and pathologists. Emory serves as a regional referral center
for cancer and over 2500 newly diagnosed patients are seen annually.
The objectives of this proposal are to improve therapy of cancer through
research and provide a database for scientific questions regarding cancer
biology, epidemiology and clinical trials methodology.
The specific aims are to increase case accruals to cooperative group
protocols and to expand Emory's participation in the science involved in
development of group protocols. Faculty members participate in Group
scientific committees. Investigations ongoing at Emory with potential for
expansion into group studies are the use of ether phospholipids as purging
agents for autologous bone marrow transplantation, the use of calcitonin
gene rearrangements for detection of minimal residual disease, combination
chemotherapy programs for autologous and allogeneic bone marrow
transplantation for lymphomas, hematopoietic growth factors on
thrombocytopoiesis, the use of viral oncolysates in melanoma, and the use
of cytokine therapy in human colorectal cancer.
Tags: Cancer Prevention, Human Therapy Evaluation, Neoplasm /cancer Genetics, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Therapy Bacillus Calmette Guerin Vaccine, Acute Leukemia, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Androgen Inhibitor, Anthracycline, Antineoplastic, Autologous Transplantation, Biological Response Modifier, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Brain Neoplasm, Breast Neoplasm, Bronchogenic Carcinoma, Calcitonin, Cancer Information System, Cancer Risk, Castration, Chemoprevention, Cis Platinum Compound, Clinical Trial, Colony Stimulating Factor, Colorectal Neoplasm, Combination Chemotherapy, Community Health Service, Cooperative Study, Cyclophosphamide, Cystectomy, Cytosine Arabinoside, Deoxycoformycin, Dyserythropoietic Anemia, Ether, Etoposide, Fluorouracil, Formamide, Gene Rearrangement, Germ Cell Neoplasm, Hairy T Cell Leukemia, Head /neck Neoplasm, Homologous Transplantation, Hormone Therapy, Ifosfamide, Interferon, Interleukin 3, Interleukin 6, Kidney Neoplasm, Leucovorin, Levamisole, Lymphocytic Leukemia, Lymphoma, Melanoma, Melphalan, Mesothelioma, Metastasis, Methotrexate, Mitomycin C, Mitoxantrone, Multiple Myeloma, Nasopharyngeal Neoplasm, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Diagnosis, Neoplasm /cancer Immunology, Neoplasm /cancer Surgery, Neoplastic Cell, Osteogenic Sarcoma, Ovary Neoplasm, Phospholipid, Prednisone, Prostate Neoplasm, Rectum Neoplasm, Sarcoma, Small Cell Carcinoma Of Lung, Tamoxifen, Therapy Compliance, Thrombopoiesis, Thyroid Neoplasm, Tumor Antigen, Urinary Bladder Epithelium, Vincristine Human Subject, Polymerase Chain Reaction, Tissue /cell Culture
Tags: Cancer Prevention, Human Therapy Evaluation, Neoplasm /cancer Genetics, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Therapy Bacillus Calmette Guerin Vaccine, Acute Leukemia, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Androgen Inhibitor, Anthracycline, Antineoplastic, Autologous Transplantation, Biological Response Modifier, Bladder Neoplasm, Bleomycin, Bone Marrow Transplantation, Brain Neoplasm, Breast Neoplasm, Bronchogenic Carcinoma, Calcitonin, Cancer Information System, Cancer Risk, Castration, Chemoprevention, Cis Platinum Compound, Clinical Trial, Colony Stimulating Factor, Colorectal Neoplasm, Combination Chemotherapy, Community Health Service, Cooperative Study, Cyclophosphamide, Cystectomy, Cytosine Arabinoside, Deoxycoformycin, Dyserythropoietic Anemia, Ether, Etoposide, Fluorouracil, Formamide, Gene Rearrangement, Germ Cell Neoplasm, Hairy T Cell Leukemia, Head /neck Neoplasm, Homologous Transplantation, Hormone Therapy, Ifosfamide, Interferon, Interleukin 3, Interleukin 6, Kidney Neoplasm, Leucovorin, Levamisole, Lymphocytic Leukemia, Lymphoma, Melanoma, Melphalan, Mesothelioma, Metastasis, Methotrexate, Mitomycin C, Mitoxantrone, Multiple Myeloma, Nasopharyngeal Neoplasm, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Diagnosis, Neoplasm /cancer Immunology, Neoplasm /cancer Surgery, Neoplastic Cell, Osteogenic Sarcoma, Ovary Neoplasm, Phospholipid, Prednisone, Prostate Neoplasm, Rectum Neoplasm, Sarcoma, Small Cell Carcinoma Of Lung, Tamoxifen, Therapy Compliance, Thrombopoiesis, Thyroid Neoplasm, Tumor Antigen, Urinary Bladder Epithelium, Vincristine Human Subject, Polymerase Chain Reaction, Tissue /cell Culture
Clinical Trials
Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Intervention: Drug: cisplatin; Drug: gemcitabine hydrochloride
More Information
Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
Intervention: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium
More Information
Active, not recruiting Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information
Intervention: Drug: dasatinib; Other: immunoenzyme technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
More Information
